Engineering the future of CAR T-cell therapies We are developing advanced therapies for cancer patients with critical unmet need ABOUT IMMPACT BIO ImmPACT Bio is developing cutting-edge potent and selective chimeric antigen receptor (CAR) T-cell technologies to address key biological challenges in treating cancer. In 2021 ImmPACT Bio merged with Kalthera Therapeutics. Learn More OUR […]

Imm Pact Bio Usa Inc. announced it raised $111 Million in an initial filing from an offering of $111 Million

Company Information

Related People

Funding Insights

Imm Pact Bio Usa Inc. announced it raised $111 Million in an initial filing from an offering of $111 Million

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information